low-grade serous carcinoma
human disease
Ratings
0
Nobody has rated this yet. Be the first!
Influences rating
Influences rating
PO004LBA/#1515 Efficacy and safety of avutometinib + defactinib in recurrent low-grade serous ovarian cancer following prior systemic therapy
ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of VS-6766 (RAF/MEK clamp) alone and in combination with defactinib (FAK inhibitor) in recurrent low-grade serous ovarian cancer (LGSOC).
#523 Initial efficacy and safety results from ENGOT-Ov60/GOG-3052/RAMP 201: a phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC)
Low-Grade Serous Ovarian Cancer: Expert Consensus Report on the State of the Science
Low-grade serous ovarian cancer: expert consensus report on the state of the science
